Literature DB >> 8757608

Different CD40-mediated signaling events require distinct CD40 structural features.

B S Hostager1, Y Hsing, D E Harms, G A Bishop.   

Abstract

Signals delivered to B cells through CD40 are critical to the development of humoral immune responses. In this study we characterize regions of the 62-amino acid cytoplasmic domain of human CD40 (hCD40) that are essential for signal transduction and examine the functional consequences of mutations in these regions. A panel of mutant hCD40 molecules was stably expressed in mouse B cell lines and tested for its ability to stimulate Ab secretion, homotypic adhesion, and increased surface expression of B7, Fas, CD23, LFA-1, and intracellular adhesion molecule-1. Our results indicate that CD40 contains at least two major signaling determinants in the cytoplasmic domain: one disrupted by a truncation of 22 amino acids, and a second disrupted by the removal of 10 additional amino acids. The second determinant includes threonine 234, a residue previously shown to be important in CD40 signal transduction. Our functional analysis of alanine and serine substitutions at position 234 indicates that phosphorylation of this residue may be important for full CD40 signaling activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757608

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

Review 2.  Fortifying B cells with CD154: an engaging tale of many hues.

Authors:  J Gordon; J D Pound
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

3.  The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Authors:  Cory Ahonen; Eric Manning; Loren D Erickson; Brian O'Connor; Evan F Lind; Steven S Pullen; Marilyn R Kehry; Randolph J Noelle
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

Review 4.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

5.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

6.  Murine B1 B cells require IL-5 for optimal T cell-dependent activation.

Authors:  L D Erickson; T M Foy; T J Waldschmidt
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

7.  Rewiring of CD40 is necessary for delivery of rescue signals to B cells in germinal centres and subsequent entry into the memory pool.

Authors:  K Siepmann; J Skok; D van Essen; M Harnett; D Gray
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

8.  Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation.

Authors:  H Nakano; S Sakon; H Koseki; T Takemori; K Tada; M Matsumoto; E Munechika; T Sakai; T Shirasawa; H Akiba; T Kobata; S M Santee; C F Ware; P D Rennert; M Taniguchi; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

9.  HOIL-1L interacting protein (HOIP) as an NF-kappaB regulating component of the CD40 signaling complex.

Authors:  Bruce S Hostager; Daniel K Fox; Douglas Whitten; Curtis G Wilkerson; Betty A Eipper; Victor P Francone; Paul B Rothman; John D Colgan
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

10.  A novel polymorphism of the human CD40 receptor with enhanced function.

Authors:  Anna L Peters; Robert M Plenge; Robert R Graham; David M Altshuler; Kathy L Moser; Patrick M Gaffney; Gail A Bishop
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.